Stada's CEO Says Top Line Growth Moved by New Products

The video discusses business strategies, focusing on top line growth through new products and geographic expansion. It highlights the challenges of cost reduction in a regulated industry and the transition to biosimilars as a response to pressures on traditional generics.

What role do regulations play in the business changes discussed by the speaker?

What is the speaker's perspective on the future of larger generic companies?